Showing 5151-5160 of 8126 results for "".
- Topix Pharmaceuticals Introduces All-Trans-Retinol Smoothing Body Lotionhttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-all-trans-retinol-smoothing-body-lotion/2458439/Topix Pharmaceuticals, Inc. has introduced All-trans-Retinol Smoothing Body Lotion, a retinol body treatment featuring layered ingredient technologies and a powerful delivery system for ultimate penetration. Replenix Smoothing Body Lotion contains the maximum dosage of retinol to be safe
- US FDA Grants Orphan Drug Status to TXA127 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/us-fda-grants-orphan-drug-status-to-txa127-for-recessive-dystrophic-epidermolysis-bullosa/2458442/The U.S. Food and Drug Administration has granted Orphan Drug Status to TXA127 as a potential treatment for the rare genetic skin disorder Recessive Dystrophic Epidermolysis Bullosa (RDEB). TXA127 developer, Tarix Orphan LLC
- Sensus Healthcare Receives Frost & Sullivan 2016 Global NMSC Therapy Technology Leadership Awardhttps://practicaldermatology.com/news/sensus-healthcare-inc-receives-frost-sullivan-2016-global-nmsc-therapy-technology-leadership-award/2458443/Sensus Healthcare, Inc. has been named the winner of the Frost & Sullivan 2016 Global Non-melanoma Skin Cancer Therapy Technology Leadership Award for its innovative therapy treatment technology. Sensus Healthcare scored an average 9.5 out of 10 possible points on the Frost & Sullivan Tec
- Santalis Pharmaceuticals Starts Phase 2 Study of New Sandalwood Oil-based AD Therapyhttps://practicaldermatology.com/news/australias-santalis-pharmaceuticals-starts-phase-2-study-of-new-ad-therapy/2458445/Santalis Pharmaceuticals has enrolled the first patient in a Phase 2 Study of 5% East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). Up to 60 patients aged 3 months to 65 with a clinically stable diagnosis of AD who have a total body surface
- Mass Spectrometry Test Helps Distinguish Atypical Moles From Melanomahttps://practicaldermatology.com/news/mass-spectrometry-test-helps-distinguish-atypical-moles-from-melanoma/2458447/Mass spectrometry may aid in the diagnosis of atypical moles, new research suggests. In this study, mass spectrometry, which analyzes the level of proteins within mole cells, correlated better than the gold standard of histologic examination to determine if an atypical mole was benign or
- Hair Transplants Make Men Look Younger, Hotterhttps://practicaldermatology.com/news/hair-transplants-make-men-look-younger-hotter/2458450/Once-balding men who undergo hair transplants are seen as more youthful, attractive, successful and approachable, new research suggests. In 2014, hair transplant was among the most common cosmetic services sought by men, with more than 11, 000 procedures performed, according to info
- FDA Greenlights NDA for New Impetigo Treatmenthttps://practicaldermatology.com/news/fda-greenlights-nda-for-new-impetigo-treatment/2458449/The U.S. Food and Drug Administration (FDA) has accepted Medimetriks Pharmaceuticals, Inc.'s New Drug Application (NDA) for their novel impetigo treatment, ozenoxacin cream, 1%. Ozenoxacin cream is a non-fluorinated quinolone. The
- Freedom Laser Therapy Launches iRESTORE Hair Growth Systemhttps://practicaldermatology.com/news/freedom-laser-therapy-launches-irestore-hair-growth-system/2458457/Freedom Laser Therapy is rolling out the iRestore Hair Growth System. The hands-free iRestore Hair Growth System is US Food and Drug Administr
- Most Indoor Tanners Not in Favor of #Banthetan Movementhttps://practicaldermatology.com/news/most-indoor-tanners-not-in-favor-of-banthetan-movement/2458464/Most young adult women who regularly visit indoor tanning salons do support the introduction of policies to make it safer, but are against a total ban. The new findings appear in Translational Behavior
- Men, New Technologies Drive Growth in Body Contouring Markethttps://practicaldermatology.com/news/men-new-technologies-drive-growth-in-body-contouring-market/2458467/The body contouring market is set to rise from $671.8 million in 2015 to more than $1.1 billion by 2022, representing a compound annual growth rate of 7.9%, according to research and consulting firm